Extraskeletal Ewing’s sarcoma/peripheral primitive neuroectodermal tumor of the small bowel presenting with gastrointestinal perforation

Abstract

Extraskeletal Ewing’s sarcoma (E-EWS)/peripheral primitive neuroectodermal tumor (pPNET) is a rare soft tissue tumor that arises from a multipotent progenitor cell and is considered to be of neuroectodermal origin. Although soft tissue E-EWS/pPNETs are common, they are exceedingly rare in the small bowel. Only 30 cases of E-EWS/pPNET of the small bowel have been reported. However, only one case of gastrointestinal perforation has been reported till today. Here, we report the second case of E- EWS/pPNET with gastrointestinal perforation.

Keywords:

• peripheral primitive neuroectodermal tumor
• immunohistochemistry
• gastrointestinal perforation
• surgery
• chemotherapy

Introduction

Ewing sarcoma (EWS) is a highly malignant bone tumor, mostly arising from long bones. The American pathologist James Ewing first described it in 1921. It is most commonly seen in children and young adults between 10 and 30 years of age. The tumor has been found in most organs including the liver, pancreas, lung, penis, prostate, vagina, esophagus, etc. However, Extraskeletal Ewing’s sarcoma/peripheral primitive neuroectodermal tumor (E-EWS/pPNET) of the small bowel is exceedingly rare with only 31 cases reported in the literature including this case. Only one case has been reported till today with gastrointestinal perforation¹ Here, we report a second case of primary E-EWS/pPNET of the small bowel presenting with gastrointestinal perforation with a brief review of the literature.

Case history

A 42-year-old male patient presented to the emergency room with chief complaints of severe abdominal pain, vomiting and not passing stool for 3 to 4 days. Physical examination revealed a pulse rate of 120/min and blood pressure of 90/60 mmHg. Abdominal examination revealed distension, tenderness, with guarding and rigidity suggesting peritonitis. Laboratory investigations revealed hemoglobin 5.2 g/dl, leukocytosis with left shift (20,000/cu mm with 90% polymorphs), alanine transaminase (ALT)90IU/L, aspartate aminotransferase (AST)20IU/L, an average random blood glucose (100 mg/dl), elevated serum creatinine (2.84 mg/dl), serum amylase (40 U/L), serum lipase (45 U/L), serum bilirubin 2.5 mg/dl, and increased C-reactive protein levels (140 mg/L). X-ray of the abdomen in erect position revealed pneumoperitoneum. Abdominal ultrasonography revealed a large amount of free fluid with internal echoes suggestive of gross peritonitis. As the patient presented in sepsis with pneumoperitoneum and severe anemia, we decided against performing computed tomography (CT) abdomen as it would not change our decision for exploratory laparotomy and only add to the delay. Initial resuscitation with packed cells (2 units), intravenous fluid and vasopressor agents was performed. Exploratory laparotomy revealed gross contamination of the peritoneal cavity with frank pus. After peritoneal lavage with warm saline, we noticed a large 8×8 cm perforated tumor in the distal jejunum (Figure 1). En bloc resection of the tumor with segmental jejunal resection was performed. The proximal end was brought out as a stoma; the distal end was closed with a feeding tube placed for nutritional purposes as a feeding jejunostomy. The specimen was sent for histopathological evaluation. Histopathological examination was suggestive of malignant round cell tumor (Figure 2), and Immunohistochemistry (IHC) was advised. Tumor cells were positive for CD99(diffuse strong) (Figure 3), synaptophysin (focal) (Figure 4), and Ki 67(80%) (Figure 5) and negative for CD3,CD20,CD5,CD10,TdT (terminal deoxynucleotidyl transferase), panCK (pancytokeratin), chromogranin and CD56. Overall the IHC profile suggested the diagnosis of pPNET. The postoperative course was unremarkable and the patient was discharged on the ninth postoperative day. The patient was referred to the oncologist for chemotherapy. A CT scan of the abdomen 2 months after surgery revealed intraperitoneal metastases without liver metastasis. The patient had under gone six cycles of chemotherapy with cyclophosphamide, vincristine and doxorubicin alternating every 3 weeks. He is at present asymptomatic and doing well on 9-month follow-up.

Figure 1 Perforated Jejunal tumor with peritonitis.

Figure 2 H& E stain (40X): Small round cells with perivesicular and pseudorosettes formation.

Figure 3 CD99: Diffuse membranous positive (40X).

Figure 4 Ki 67 nuclear positive (40X).

Figure 5 Synaptophysin cytoplasmic focal positive.

The patient provided written informed consent for publication of his case details and images.

Discussion

The Ewing sarcoma family of tumors, a subgroup of small-round-cell tumors characterized by specific recurrent translocations (usually EWSR1/FLI1) include Ewing Sarcoma and Primitive neuroectodermal tumors.² James Ewing was the first to describe EWS in 1921. PNET is an uncommon aggressive malignancy of the bone occurring mainly in childhood and adolescence.³ It is difficult for pathologists to differentiate between EWS and PNET due to overlapping of the genetic abnormality. Therefore, they no longer categorize EWS and PNET as different tumors.³ The distinction lies merely in their degree of differentiation; therefore the 2013 update to the World Health Organization pathology classification system has removed all distinction between PNET and ES.⁴ The terms are used interchangeably as they represent opposite ends of a spectrum (with PNET being more primitive, despite the name) and because of their common biology, they are treated in common protocols. Batsakis et al divided PNET family of tumors into three groups based on the tissue of origin:⁵ CNS primitive neuroectodermal tumors (PNETs), neuroblastoma and peripheral primitive neuroectodermal tumors (pPNETs). We shall focus on pPNET in this review.

Most pPNETs occur between the first and third decades of life with a peak incidence in the second decade. Our patient was, unusually, 42 years of age. It is traditionally believed that the outcome is worse in older patients based on stratification in younger cohorts. However, recent studies suggest that age may not be a negative determinant of survival prognosis.^6,7 This may be due to intensified chemotherapy and wider use of surgery, but the question is still open.⁸

The most common locations for pPNET are the chest wall, extremities, and retroperitoneal region. However, a tumor originating from the small intestine is rare.

We performed an extensive literature search using the terms:“E-EWS”, “PNET”, “small bowel”, “gastrointestinal perforation”, on various search engines including PubMed, Embase,GoogleScholar and Semantic Scholar. Since the first report in 2,000 by Horie et al¹ a total of 30 cases have been described worldwide. Table 1 summarizes previously reported small bowel E-EWS/pPNET cases, including our case. We analyzed the cases reported till date using descriptive statistics. Among the reported cases, including our case, there were 16 males and 15 females, with an average age at presentation of 36.7 years (range: 9–63 years); 2 (6.45%) cases were aged <12years (child), while 8(25.80%) cases were in the age group of 12–18 years (adolescent).Eight patients(25.80%) were over 40 years. Thirteen patients (41.93%) were between 20 and 40 years of age. Its incidence (41.93%) is highest in the 20–40 years’ age-group and it is quite rare (6.45%) in children less than 12 years. The peak incidence of EWS is between 10 and 20 years of age. Our analysis does not match this traditional belief. We found that 67.74% cases were over 20 years of age. The location of the E-EWS/PNET within the small bowel in descending order was: ileum 19cases (61.29%), jejunum 7cases (22.58%) and duodenum 2 cases (6.45%); in 3 (9.67%) cases the exact location within the small bowel was not specified. The present example describes an unusual presentation, namely the perforation. The ileum is most commonly involved, and jejunal involvement is rare. The most common presentation in this analysis was abdominal lump/mass in 7 cases (22.58%) followed by iron deficiency anemia in 5(16.12%), intestinal obstruction in 4(12.90%), gastrointestinal perforation including our case 2 (6.45%), and liver metastases in 2(6.45%) cases.The presentation was not documented in 5 cases at the first visit. Therefore, the most common presentation in the review was abdominal lump/mass and the least common was gastrointestinal perforation. Perforation was considered to be caused by tumor necrosis or local ischemic changes. Our case is the second case of gastrointestinal perforation in small intestine E-EWS/pPNET. We also reviewed the management in such cases and found that 27 patients underwent surgical resection, two patients were treated from a core biopsy, while for one patient information was not available.

Table 1 Cases of E-EWS/pPNET of the small bowel, reported in the English literature to date

Sr.No	Authors	Year	Age/sex	Location	Clinical presentation	Treatment	IHC markers	Follow up
1	Hori and Kato^Citation1	2000	40/M	Jejunum	Intestinal perforation	Sx + Cx	CD99,NSE,Synand Vimentin	Died after 5 mo
2	Graham, et al^Citation9	2000	14/M	Ileum	IDA with abdominal lump	Sx+Cx	CD99,CK	10 mo DFS
3	Sarangarajna, et al^Citation10	2001	13/M	Jejunum	SBO	SX	CD 99,CK	12 mo DFS
4	Shek, et al^Citation11	2001	9/F	SB	Abdominal distension	Sx +Cx	CD99	Died 25 mo after Sx
5.	Adair, et al^Citation12	2001	21/F	Duodenum	vomiting	Sx+Cx	CD99,CK	10 mo DFS
6	Balasubramanian, et al^Citation13	2002	53/F	Ileal mesentery	Abdominal mass	Sx	CD99	ND
7	Kie, et al^Citation14	2003	20/F	Duodenum	Ulcer	Sx+Cx	CD99	18 moDFS
8	Boehm, et al^Citation15	2003	18/M	Ileum	Intussusception(SBO)	Sx +Cx	CD99(Neg)	ND
9	Bala, et al^Citation16	2006	57/F	Ileum	Mass	Sx	Vimentin,NSE,O-13,c-kit,FLI1	8 mo DFS
10	Kim, et al^Citation17	2007	63/M	Ileum	SBO	Sx	CD99,CD117	ND
11	Sethi and Smith^Citation18	2007	44/M	Ileum	SBO	Sx	CD99,NSE	Died at 13 mo
12	Rodarte-Shade, et al^Citation19	2012	32/M	SB	IDA	Sx+Cx	FLI1,CD99	6 mo DFS
13	Vignali, et al^Citation20	2012	15/F	Ileum	Mass	Sx+Cx	CD99(Neg)	ND
14	Prasertvit, Stoikes^Citation21	2013	28/F	SB	ND	ND	CD99	ND
15	Kim, et al^Citation22	2013	23/M	Jejunal mesentery	Tumor rupture without GI perforation	Sx+Cx	CD57,NSE	Recurrence at 1 year
16	Milione, et al^Citation23	2014	18/M	Ileum	Liver mets	Core biopsy	CD99,FLI1	Died 8 mo after diagnosis
17	Milione, et al^Citation23	2014	20/M	Ileum	Liver mets	Core biopsy	CD99,FLI1	DOD at 28 mo
18	Milione, et al^Citation23	2014	42/M	Ileum	ND at presentation. Liver mets on follow-up	Sx+Cx	CD99,FLI1	DOD at 11 mo
19	Milione, et al^Citation23	2014	45/M	Ileum	ND at presentation.Liver mets on follow-up	Sx+Cx	CD99,FLI1	DOD at 13 mo
20	Milione, et al^Citation23	2014	15/F	Ileum	ND	Sx+Cx+Radiotherapy	CD99,FLI1	AW at 28 mo
21	Milione, et al^Citation23	2014	27/M	Ileum	ND	Sx	CD99,FLI1	lost
22	Milione, et al^Citation23	2014	28/F	Ileum	ND at presentationbut on follow-up liver, lung, stomach and peritoneum metastases	Sx	CD99,FLI	AW at 204 mo
23	Padma, et al^Citation24	2015	22/F	Jejunum	Mass	Sx	CD99,S 100	ND
24	Peng, et al^Citation25	2015	59/M	Ileum	Abdominal pain	Sx+Cx	CD99,FLI	Lost
25	Peng, et al^Citation25	2015	22/M	Ileocecum	Mass with metastases	Sx	CD99,FLI	Lost
26	Peng, et al^Citation25	2015	36/F	Ileocecum	Mass	Sx	CD99,FLI	DOD at 34 mo
27	Liu, et al^Citation26	2016	15/M	Jejunum	Hematemesis,Melena,IDA	Sx	CD99, vimentin, syn, CD56 and NSE	Died at 3 mo
28	Li, et al^Citation27	2017	16/F	Ileum	IDA	Sx	Vimentin, CD99, and Syn	DFS 10mo
29	Kim, et al^Citation28	2017	9/F	Jejunum	IDA with peritoneal metastases	Neoadjuvant Cx+Sx+Adjuvant Cx	CD99,EWS FLI1	ND
30	Liao, et al^Citation29	2018	25/F	Ileum	Mass	Sx	CD99, vimentin,FLI1	Lost
31	Our case	2019	42/M	Jejunum	Perforation	Sx+Cx	CD99,syn, Ki 67	AWD at 9 months

Abbreviations: M, Male; F, Female; IHC, Immunohistochemistry; Sx, Surgery; Cx, Chemotherapy; NSE, Neuron-specific enolase; Syn, Synaptophysin; DFS, Disease free survival; SBO, Small bowel obstruction; CK, Cytokeratin; ND, not documented; IDA, Iron deficiency anemia; SB, Small bowel; AW, alive and well; AWD, alive with disease; DOD, dead of disease; mo, month(s); mets, metastasis.

Histologically, Homer-Wright or Flexner-Wintersteiner rosettes and perivascular pseudorosettes may form from undifferentiated small round cells which constitute pPNET²⁷ The panel suggested by Mhawech-Fauceglia et al³⁰ for the diagnosis of EWS/PNET is a combination of CD99 and FLI1. A few other studies also establish the utility of CD99 for the determination of EWS/PNET.^31–33 However, it has also been found in synovial sarcoma, rhabdomyosarcoma and desmoplastic small round cell tumor.^34,35 EWS shows diffuse membranous positivity for CD99 whereas synovial sarcoma shows strong cytoplasmic positivity.³⁵ In the present case, we found a diffuse membranous positivity for CD99. In this review, CD99 was positive in 27 out of 29 cases, and in 2 cases CD 99 was negative while in two examples it was not documented. We found 93.10% positivity for CD 99 for the small bowel pPNET. FLI1 is a specific marker for ES. However, it is variably positive in lymphoblastic lymphoma³⁶ In the above analysis FLI1 was not done in 18 cases (58.06%). Kim et al²⁸ also observed that FLI1 was not done in 56% cases. Vimentin is also a useful marker and usually positive while S100, chromogranin A, synaptophysin, and neuron-specific enolase show variable sensitivity.³¹ In small bowel PNET, Vimentin was documented in only 5 cases (16.1%). We did a panel of negative IHC markers like CD3, CD20, CD5, CD10,TdT to exclude lymphoma, panCK to rule our epithelial cell tumor and desmoplastic small round cell tumor, chromogranin and CD56 to rule out the neuroendocrine tumor and Desmin to rule out rhabdomyosarcoma. Recently, Yoshida et al³⁷ reported that the NKX2.2 gene is a valuable marker for PNET, with a sensitivity of 93% and a specificity of 89%. EWS/FLI1 fusion is sometimes advised to confirm the diagnosis particularly in older patients and/or at unusual location,although sometimes these tests may be negative;³⁸, Identification of the different gene fusion may add prognostic value to existing fluorescence in situ hybridization assays,³⁹ Recently, twenty-five cases of intestinal PNET were reviewed by Liao et al²⁹ they found that RT-PCR EWS-FLI1 was documented only in 16 patients (64%) and FISH break apart EWSR1 was documented in 14 cases (56%). Both of these were not documented in 24% cases.

For E- EWS/pPNET developing in the small bowel, there are no standard protocols. Surgery alone is associated with poor outcome. Therefore, enbloc resection with systemic adjuvant chemotherapy is primarily chosen for local and systemic control as for other ES/PNET.²⁵ The longest reported survival was 204 months²³ and the shortest was 3 months.²⁶ The commonest cause of death was metastatic disease.

Conclusion

E-EWS/pPNET of the small bowel is exceedingly rare. Gastrointestinal perforation has been reported in only one case till today and this is the second case. Contrary to traditional belief,we observed that E-EWS/pPNET of the small bowel is common in patients over 20 years of age (67.74%). We found abdominal lump to be the most common presentation, and perforation the least common.CD99 was positive in 93.10% and FLI1 was not done in majority of cases (58.06%). Although, CD99 was positive in other round cell tumors, but diffuse membranous positivity along with negative lymphoma, epithelial cell, neuroendocrine, and rhabdomyosarcoma markers suggest E-EWS/pPNET.EWS-FLI1 gene fusion has additional prognostic value. En bloc resection with systemic adjuvant chemotherapy is primarily chosen for local and systemic control as for other E-EWS/pPNET.

Institutional approval

Institutional approval is neither applicable nor required for publication of this manuscript.

Acknowledgments

We would like to acknowledge the help provided by Dr Bhavna Mehta, consultant histopathologist, Supratech Micropath laboratory, Ahmedabad (Gujarat, India) for providing wonderful images of histopathology and IHC.

Disclosure

The authors report no conflicts of interest in this work.